Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
{{output}}
Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies examining salvage th... ...
